ATE256730T1 - Rekombinante mykobakterielle expressions-träger sowie deren verwendung - Google Patents

Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Info

Publication number
ATE256730T1
ATE256730T1 AT89908028T AT89908028T ATE256730T1 AT E256730 T1 ATE256730 T1 AT E256730T1 AT 89908028 T AT89908028 T AT 89908028T AT 89908028 T AT89908028 T AT 89908028T AT E256730 T1 ATE256730 T1 AT E256730T1
Authority
AT
Austria
Prior art keywords
mycobacteria
recombinant
mycobacterial
vector
coli
Prior art date
Application number
AT89908028T
Other languages
English (en)
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Robert N Husson
Original Assignee
Whitehead Biomedical Inst
Einstein Coll Med
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Einstein Coll Med, Univ Leland Stanford Junior filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE256730T1 publication Critical patent/ATE256730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89908028T 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung ATE256730T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21639088A 1988-07-07 1988-07-07
US22308988A 1988-07-22 1988-07-22
US07/361,944 US5504005A (en) 1987-03-02 1989-06-05 Recombinant mycobacterial vaccine
PCT/US1989/002962 WO1990000594A2 (en) 1988-07-07 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor

Publications (1)

Publication Number Publication Date
ATE256730T1 true ATE256730T1 (de) 2004-01-15

Family

ID=27396269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89908028T ATE256730T1 (de) 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Country Status (8)

Country Link
US (5) US5504005A (de)
EP (1) EP0424437B1 (de)
JP (2) JP3485916B2 (de)
AT (1) ATE256730T1 (de)
AU (1) AU3867789A (de)
CA (1) CA1339526C (de)
DE (1) DE68929507T2 (de)
WO (1) WO1990000594A2 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
EP0400973B1 (de) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
CA2063414A1 (en) * 1989-06-19 1990-12-20 Richard A. Young Vector-mediated genomic insertion and expression of dna in bcg
CA2076753A1 (en) * 1990-02-26 1991-08-27 Anthony J. Radford Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
GB9015888D0 (en) * 1990-07-19 1990-09-05 Smithkline Biolog Vectors
AU643842B2 (en) * 1990-10-25 1993-11-25 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
WO1992007582A1 (en) * 1990-10-25 1992-05-14 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
EP0587775A4 (de) * 1991-06-06 1994-11-02 Medimmune Inc Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene.
WO1992021374A1 (en) * 1991-06-06 1992-12-10 Medimmune, Inc. Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments
FI935566A0 (fi) * 1991-06-13 1993-12-10 Einstein Coll Med Insertionsmutationer i mycobakterier
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (de) 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
US6300061B1 (en) 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
US5750384A (en) * 1992-02-07 1998-05-12 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University L5 shuttle phasmids
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
ATE212378T1 (de) * 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
ES2313719T3 (es) 1993-11-23 2009-03-01 The Regents Of The University Of California Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
FR2720076B1 (fr) * 1994-05-20 1996-08-02 Inst Nat Sante Rech Med Vecteurs navettes pour l'introduction d'ADN dans des mycobactéries et utilisation de ces bactéries comme vaccins.
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU6029898A (en) * 1997-01-21 1998-08-07 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
EP1047451A1 (de) * 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Verwendung von hitzeshockproteinen zur verabreichung von einheiten in zellen
ATE231917T1 (de) 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
AU3710597A (en) 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
CA2245408A1 (en) * 1997-08-21 1999-02-21 York University High-throughput screens for enzyme inhibitors
EP0902086A1 (de) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
US6387694B1 (en) 1998-04-03 2002-05-14 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial isocitrate lyase gene and uses thereof
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1196772A2 (de) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
AU1814101A (en) 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
DE60139963D1 (de) * 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
WO2002036777A1 (en) 2000-11-02 2002-05-10 The National University Of Singapore aopB GENE, PROTEIN, HOMOLOGS, FRAGMENTS AND VARIANTS THEREOF, AND THEIR USE FOR CELL SURFACE DISPLAY
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US7722861B2 (en) * 2002-02-19 2010-05-25 Svetoslav Bardarov, legal representative Attenuated Mycobacterium tuberculosis vaccines
US7758874B2 (en) * 2002-02-19 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated Mycobacterium tuberculosis vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
CN100572540C (zh) * 2002-04-16 2009-12-23 成都永安制药有限公司 包括表达丙氨酸脱氢酶、丝氨酸脱水酶和/或谷氨酰胺合成酶的重组卡介苗菌株的结核病疫苗
WO2004001020A2 (en) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
WO2004016280A1 (ja) * 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えｂｃｇワクチン
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2004066928A2 (en) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Use of mycobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
EP2206514B1 (de) 2003-10-16 2014-01-08 The Regents of The University of California Rekombinante, intrazelluläre, immunogene Pathogenzusammensetzungen und Verwendungsverfahren
US8163294B2 (en) * 2003-10-16 2012-04-24 The Regents Of The University Of California Growth regulatable recombinant BCG compositions
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060002956A1 (en) * 2004-04-05 2006-01-05 Surber Mark W Minicells as vaccines
US7998471B2 (en) * 2005-01-12 2011-08-16 Albert Einstein College Of Medicine Of Yeshiva University Mycobacteria expressing HIV-1 and malaria antigens
AU2006204907B2 (en) * 2005-01-12 2011-08-11 Albert Einstein College Of Medicine, Inc. Mycobacterial mutants affecting host apoptosis
US20090017061A1 (en) 2005-01-18 2009-01-15 Bernard Jan Appelmelk Mycobacteria with Mannose Cap-Deficient Lipoarabinomannan
JP2009502747A (ja) * 2005-07-14 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア １−メチル−ピラゾール−４−イルカルボキシアニリド類に基づく殺菌性混合物
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
WO2007067729A2 (en) 2005-12-09 2007-06-14 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
US8101191B2 (en) * 2006-01-12 2012-01-24 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial SecA2 mutants
EP3351268B1 (de) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Behandlung von immunerkrankungen durch mukosale abgabe von antigenen
US8591918B2 (en) 2007-03-19 2013-11-26 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants inducing IL-12
AU2007352618B2 (en) 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
RU2392002C2 (ru) * 2008-04-02 2010-06-20 ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова Способ получения туберкулезного анатоксина
RU2372936C1 (ru) * 2008-05-19 2009-11-20 Закрытое акционерное общество "Томские клеточные технологии" (ЗАО "Томские клеточные технологии") Способ получения аутологичной вакцины для лечения туберкулеза
CN102712680B (zh) 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
EP3527222B1 (de) 2011-02-15 2021-04-07 Vaxiion Therapeutics, LLC Therapeutische zusammensetzungen und verfahren für auf antikörper- und fc-haltigen molekülen basierende gezielte verabreichung bioaktiver moleküle durch bakterienminizellen
EP2750694B8 (de) 2011-08-08 2018-11-14 Curelab Oncology, Inc. Verfahren und zusammensetzungen im zusammenhang mit p62 zur behandlung und prophylaxe von krebs
WO2013059616A1 (en) * 2011-10-21 2013-04-25 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
WO2014032835A1 (en) 2012-08-31 2014-03-06 Laboratorios Del Dr. Esteve, S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
EP2895501B1 (de) 2012-09-17 2017-01-18 Novartis Tiergesundheit AG Salmonid alphavirus und verwendungen davon
US9809863B2 (en) 2012-11-02 2017-11-07 Elanco Tiergesundheit Ag Flavivirus associated with Theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
CN106061501A (zh) 2013-12-29 2016-10-26 Cl昂科莱吉有限公司 用于治疗和预防炎症相关疾病的涉及p62/sqstm1的方法和组合物
CA2957258C (en) 2014-08-05 2023-11-07 MabQuest SA Immunological reagents
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
ES3034233T3 (en) 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
CN109312409A (zh) * 2016-03-31 2019-02-05 金山大学,约翰内斯堡 耻垢分枝杆菌的遗传修饰株
JP2019520075A (ja) * 2016-06-30 2019-07-18 テクノロジー イノベーション モメンタム ファンド（イスラエル）リミテッド パートナーシップＴｅｃｈｎｏｌｏｇｙ Ｉｎｎｏｖａｔｉｏｎ Ｍｏｍｅｎｔｕｍ Ｆｕｎｄ（ｉｓｒａｅｌ）Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ 広範囲の宿主範囲を有するバクテリオファージバリアント、核酸を目的の宿主に形質導入する際のその調製方法及び用途
US11944679B2 (en) 2017-03-14 2024-04-02 The Regents Of The University Of California Genome-wide identification of immune evasion functions in a virus
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
EP3996815A2 (de) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv-bindemittel
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
JP2024512499A (ja) * 2021-03-22 2024-03-19 クリップスビーエヌシー・カンパニー・リミテッド 新規な組換えマイコバクテリウムスメグマチス菌株およびその用途
CA3230802A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59205983A (ja) * 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
US4743546A (en) * 1985-02-13 1988-05-10 Biotechnica International, Inc. Controlled gene excision
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
EP0347425B1 (de) * 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Rekombinant-mykobakterielle impfstoffe

Also Published As

Publication number Publication date
JPH04500305A (ja) 1992-01-23
US5968733A (en) 1999-10-19
US5854055A (en) 1998-12-29
WO1990000594A3 (en) 1990-05-03
WO1990000594A2 (en) 1990-01-25
US5504005A (en) 1996-04-02
EP0424437A1 (de) 1991-05-02
DE68929507T2 (de) 2004-09-23
US6372478B1 (en) 2002-04-16
US6270776B1 (en) 2001-08-07
JP3485916B2 (ja) 2004-01-13
DE68929507D1 (de) 2004-01-29
EP0424437B1 (de) 2003-12-17
JP2000350578A (ja) 2000-12-19
AU3867789A (en) 1990-02-05
CA1339526C (en) 1997-11-04

Similar Documents

Publication Publication Date Title
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
KR940010865B1 (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
EP0856059B1 (de) Verfahren zur herstellung von rekombinanten plasmiden
AU5848090A (en) Vector-mediated genomic insertion and expression of dna in bcg
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
DE3854840D1 (de) Rekombinant-mykobakterielle impfstoffe
ATE214100T1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
AU3041295A (en) Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
EP1363660A4 (de) "überlegene molekulare vakzine auf basis selbstreplizierender rna, suizid-dna oder nacktem dna-vektor, zur verknüpfung von antigen mit polypeptid zur förderung der antigenpräsentation"
IL133056A (en) Polypeptide containing an immunogenic portion of an m. tuberculosis antigen, a variant thereof and pharmaceutical compositions containing same
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
JP2001514000A5 (de)
IE821428L (en) Foot and mouth disease vaccine
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
IL90035A (en) Synthetic multimeric hepatitis b virus vaccine including both t cell and b cell determinants
KR970703165A (ko) 미코박테리아성 감염에 대한 백신(vaccine against mycobacterial infections)
Haeseleer et al. Stable integration and expression of the Plasmodium falciparum circumsporozoite protein coding sequence in mycobacteria
AU2387892A (en) Nucleotide sequences and resistance proteins cycloheximide
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
AU5776799A (en) Modified hcv peptide vaccines
CA2446260A1 (en) Novel expression vectors and uses thereof
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
KR920006503A (ko) 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties